EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC 4.0

Rituximab versus placebo for chronic inflammatory demyelinating polyradiculoneuropathy: a randomized trial

Eduardo Nobile-Orazio, Dario Cocito, Fiore Manganelli iD, Raffaella Fazio, Giuseppe Lauria Pinter iD, Luana Benedetti, Anna Mazzeo, Erdita Peci, Emanuele Spina, Yuri Falzone, Eleonora Dalla Bella, Francesco Germano und 6 weitere

Brain · 03.04.2025 · 148 (4) · 1112-1121

DOI: 10.1093/brain/awae400 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Brain, online erschienen am 10.12.2024. Verfasst von Eduardo Nobile-Orazio und 17 weiteren Autor:innen. Beteiligte Einrichtung: Neuromuscular and Neuroimmunology Unit, IRCCS Humanitas Research Hospital, Milan, Rozzano 20089, Italy. Hauptthemen laut MEDLINE: Rituximab, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, Immunologic Factors. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Associazione Italiana Farmaco, CIDP Foundation International.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) often requires prolonged ongoing treatment to prevent worsening. The efficacy of rituximab in preventing worsening after the discontinuation of immunoglobulin therapy in patients with CIDP was assessed. In this randomized, double-blind, placebo-controlled study, conducted at seven Italian hospitals, CIDP patients under immunoglobulin therapy were assigned to receive either rituximab (1 g on Days 1, 15 and 180 ± 7) or placebo. Both groups continued their regular immunoglobulin doses for 6 months post-intervention. The primary end point was the proportion of patients who worsened in any of the following three measures at Month 12, within 6 months after immunoglobulin discontinuation: a decrease of at least one point on the adjusted INCAT score, two points on the MRC sum score, or four points on the RODS centile score. Secondary end points included the proportion of patients deteriorating at Month 18 (within 12 months after immunoglobulin discontinuation), treatment cessation due to adverse events or voluntary reasons, and the time until deterioration after immunoglobulin discontinuation. This study was registered with ClinicalTrials.gov (NCT06325943) and EUDRACT (number 2017-005034-36), and is now complete. From April 2019 to March 2022, 39 patients were recruited; two withdrew consent. The remaining 37 patients were assigned to rituximab (n = 19) or placebo (n = 18). Median age was 53 (interquartile range 45–64), with 11 (30%) females. A similar proportion of patients in both the rituximab (12/19, 63.2%) and placebo (12/18, 66.6%) groups worsened at Month 12 [odds ratio (OR) 0.86; 95% confidence interval (CI) 0.22–3.32]. No significant differences were noted at Month 18 (OR 0.62; 95% CI 0.14–2.70), or in the mean scores of each scale at Months 6, 12 and 18. The median time to worsening was 5 months for rituximab and 2 months for placebo (Log-rank P = 0.4372). Treatment was suspended due to adverse events in one rituximab patient. In this study, rituximab was not more effective than placebo in preventing clinical deterioration following the discontinuation of immunoglobulin therapy in CIDP. Further studies might evaluate the efficacy of more frequent or earlier administration of rituximab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RituximabPolyradiculoneuropathy, Chronic Inflammatory DemyelinatingImmunologic FactorsHumansFemaleMaleMiddle AgedDouble-Blind MethodAgedTreatment OutcomeAdultImmunoglobulins, Intravenous

Stichwörter der Autor:innen

CIDPrandomized clinical trialrandomized controlled trialtherapy: immunosuppressive therapytreatment

Substanzen

RituximabImmunologic FactorsImmunoglobulins, Intravenous

Autor:innen und Institutionen

  • Neuromuscular and Neuroimmunology Unit, IRCCS Humanitas Research Hospital, Milan, Rozzano 20089, Italy.
  • Department of Medical Biotechnology and Translational Medicine, Milan University, Milano 20133, Italy.
  • Department of Clinical and Biological Sciences, University of Turin, Torino 10124, Italy.
  • Department of Neuroscience, Reproductive Sciences and Odontostomatology, University of Naples 'Federico II', Napoli 80131, Italy.
  • Division of Neuroscience, Department of Neurology, Institute of Experimental Neurology (INSPE), San Raffaele Scientific Institute, Milano 20132, Italy.
  • Unit of Neuroalgology, IRCCS Foundation 'Carlo Besta' Neurological Institute, Milano 20133, Italy.

ORCID-Profile: Fiore Manganelli, Giuseppe Lauria Pinter, Giuseppe Liberatore, Roger Collet-Vidiella

Förderung

  • Associazione Italiana Farmaco
  • CIDP Foundation International

Zitieren

APA

Nobile-Orazio, E., Cocito, D., Manganelli, F., Fazio, R., Lauria Pinter, G., Benedetti, L., Mazzeo, A., Peci, E., Spina, E., Falzone, Y., Dalla Bella, E., Germano, F., Gentile, L., Liberatore, G., Gallia, F., Collet-Vidiella, R., Bianchi, E., & Doneddu, P. E. (2025). Rituximab versus placebo for chronic inflammatory demyelinating polyradiculoneuropathy: a randomized trial. Brain, 148(4), 1112-1121. https://doi.org/10.1093/brain/awae400

Vancouver

Nobile-Orazio E, Cocito D, Manganelli F, Fazio R, Lauria Pinter G, Benedetti L, et al. Rituximab versus placebo for chronic inflammatory demyelinating polyradiculoneuropathy: a randomized trial. Brain. 2025;148(4):1112-1121. doi:10.1093/brain/awae400

BibTeX
@article{NobileOrazio2025,
  author = {Nobile-Orazio, Eduardo and Cocito, Dario and Manganelli, Fiore and Fazio, Raffaella and Lauria Pinter, Giuseppe and Benedetti, Luana and Mazzeo, Anna and Peci, Erdita and Spina, Emanuele and Falzone, Yuri and Dalla Bella, Eleonora and Germano, Francesco and Gentile, Luca and Liberatore, Giuseppe and Gallia, Francesca and Collet-Vidiella, Roger and Bianchi, Elisa and Doneddu, Pietro Emiliano},
  title = {Rituximab versus placebo for chronic inflammatory demyelinating polyradiculoneuropathy: a randomized trial},
  journal = {Brain},
  year = {2025},
  volume = {148},
  number = {4},
  pages = {1112--1121},
  doi = {10.1093/brain/awae400}
}
Kostenlos starten →